Di Yu
Forskare vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Magnus Essand
- Mobiltelefon:
- 070-720 41 96
- E-post:
- di.yu@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Denna text finns inte på svenska, därför visas den engelska versionen.
Post Doc at Dept. Immunolgy, Genetics and Pathology
My research is focused on viruses-/T cell- based cancer therapy. Group leader: Magnus Essand
Publikationer
Urval av publikationer
- Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures (2013)
- Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors (2011)
Senaste publikationer
- Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment (2023)
- CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- Complementarity-determining region clustering may cause CAR-T cell dysfunction (2023)
- A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products (2022)
Alla publikationer
Artiklar
- Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment (2023)
- CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours (2023)
- Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma (2023)
- Complementarity-determining region clustering may cause CAR-T cell dysfunction (2023)
- A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products (2022)
- Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-turnor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response (2022)
- CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers (2022)
- Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses (2022)
- Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus (2021)
- IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma (2021)
- In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy (2021)
- Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19 (2021)
- Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer (2020)
- Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models (2018)
- Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses (2018)
- Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis (2018)
- CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis (2018)
- Modifying melanoma immune microenvironment by heterologous prime-boost vaccination with adenovirus and Modified Vaccinia Ankara virus vectors (2018)
- Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth (2018)
- CAR T-Cells with Induced Secretion of Helicobacter Pylori Neutrophil-Activating Protein (HP-NAP) Yields Improved Anti-Tumor Activity and Reduced Immunosuppression (2017)
- Adenovirus, Semliki Forest virus and vaccinia virus-induced immunogenic cell death augments oncolytic virus immunotherapy (2017)
- Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus (2017)
- Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity (2017)
- Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth (2017)
- Multiple viruses rely on the stress-induced protein ZC3H11A for efficient replication (2017)
- Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer (2017)
- Allogeneic dendritic cells (AlloDCs) transduced with an infection enhanced adenovirus as adjuvant for cancer immunotherapy (2016)
- Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer (2016)
- Long-term episomal gene transfer for safe engineering of T cells for adoptive cell therapy of cancer (2016)
- Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors (2016)
- A Multiplex Protein Panel Applied to Cerebrospinal Fluid Reveals Three New Biomarker Candidates in ALS but None in Neuropathic Pain Patients (2016)
- HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice (2016)
- Chondroitin Sulfate-Coated DNA-Nanoplexes Enhance Transfection Efficiency by Controlling Plasmid Release from Endosomes (2015)
- Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. (2015)
- Long-term episomal gene transfer for safe engineering of T-cells for adoptive cell therapy of cancer (2014)
- Allogeneic lymphocyte-licensed DCs expand T cells withimproved antitumor activity and resistance to oxidative stress andimmunosuppressive factors (2014)
- Allogeneic Lymphocyte-Licensed DCs Expand TCR/CAR-Engineered T Cells, Which Are Insensitive To Oxidative Stress and Immunosuppressive Factors (2014)
- A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells (2014)
- Vector-Encoded Helicobacter pylori Neutrophil-Activating Protein Promotes Maturation of Dendritic Cells with Th1 Polarization and Improved Migration (2014)
- Adenovirus Encoded Helicobacter pylori Neutrophil Activating Protein Promotes Maturation of DCs with Th-1 Polarization, Improved Antigen Presentation and Migration (2014)
- Tat‐PTD‐modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy (2013)
- An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors (2013)
- Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures (2013)
- Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells (2011)
- Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors (2011)
- Tumor antigen-loaded allogeneic dendritic cells augment therapeutic effect of adoptively transferred T-cells by altering tumor immune-microenvironment
- Therapeutic vaccination of HPV-associated tumors using pro-inflammatory allogeneic dendritic cells and an HPV-E6/E7-encoding vector
- Concomitant targeting of PD-1 or CD137 enhances the effect of adjuvant pro-inflammatory allogeneic dendritic cells.
- CD19 CAR T-cells with induced secretion of Helicobacter Pylori Neutrophil-Activating Protein (HP-NAP) yields improved anti-tumor activity and reduced immunosuppression
- Preclinical evaluation of CAR20(NAP)-T cells for B cell lymphoma
- Armed CAR-T cells directed against IL13Rα2 show potent activity against glioblastoma
- Complementary-determining region clustering causes CAR-T cell dysfunction
Böcker
